A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...

Background: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been ... did not receive any inhaled medication. Spirometry was performed ...

This includes steroid-containing combinations and long-acting bronchodilators ... should be the foundation treatment for the majority of symptomatic COPD patients. In the CRYSTAL study, patients ...

Conclusion: Tiotropium appears to be at least as effective as currently available alternatives in the treatment of patients with COPD who require daily bronchodilator treatment. Its simplified ...

Current treatment options for COPD include bronchodilators such as beta2-agonists and anticholinergics, standalone or combination inhaled corticosteroids (ICS), and other combination medications.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated ...

Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...

After Diwali celebrations, the air quality in Gurgaon has significantly deteriorated, leading to a sharp rise in respiratory ...

Gangdong Kyunghee University Hospital (Director Lee Woo-in) won the first grade in the 9th COPD adequacy evaluation announced ...